Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study
机构：[1]National Clinical Research Center for Obstetric & Gynecologic Diseases, and Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[2]Sichuan Cancer Hospital & Institute, Chengdu, China四川省肿瘤医院[3]West China Second University Hospital, Sichuan University, Chengdu, China[4]Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, China[5]The First Affiliated Hospital of Anhui Medical University, Hefei, China[6]The First Affiliated Hospital of Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[7]Xinqiao Hospital Army Medical University, Chongqing, China[8]Peking University BinHai Hospital, Tianjin, China[9]The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China[10]The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China中山大学附属第三医院[11]The Third Affiliated Hospital of Southern Medical University, Guangzhou, China[12]The First People's Hospital of Yunnan Province, Kunming, China云南省第一人民医院[13]First Affiliated Hospital of Kunming Medical University, Kunming, China昆明医科大学附属第一医院[14]The Second Hospital of Jilin University, Changchun, China[15]Qilu Hospital of Shandong University, Jinan, China[16]The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China[17]China-Mongolia Hospital of Ulanqab, Ulanqab, China[18]The Women's Hospital School of Medicine Zhejiang University, Hangzhou, China浙江大学医学院附属妇产科医院[19]Fujian Provincial Maternal and Child Health Care Hospital, Fuzhou, China[20]Tianjin First Central Hospital, Tianjin, China[21]Key Laboratory of Protein Engineering and Drug Development of Hainan, Haikou, China[22]SR Life Sciences Institute, MD, USA
This research was supported by the Beijing Union Medical College
Hospital & Central Higher Hospital Clinical Research Special Fund (No.
2022-PUMCH-D-003).
第一作者机构：[1]National Clinical Research Center for Obstetric & Gynecologic Diseases, and Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
通讯作者：
通讯机构：[1]National Clinical Research Center for Obstetric & Gynecologic Diseases, and Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[*1]No.1 ShuaifuyuanWangfujing Dongcheng District, Beijing 100730, China.
推荐引用方式(GB/T 7714)：
Chen Fei,Zhang Guo-Nan,Lei Wei,et al.Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study[J].GYNECOLOGIC ONCOLOGY.2023,178:8-13.doi:10.1016/j.ygyno.2023.09.004.
APA：
Chen Fei,Zhang Guo-Nan,Lei Wei,Zhou Shu-Guang,Zhang Ying...&Lang Jing-He.(2023).Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study.GYNECOLOGIC ONCOLOGY,178,
MLA：
Chen Fei,et al."Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study".GYNECOLOGIC ONCOLOGY 178.(2023):8-13
医学